Details for Patent: 8,859,610
Which drugs does patent 8,859,610 protect, and when does it expire?
Patent 8,859,610 protects QBREXZA and is included in one NDA.
This patent has twenty-nine patent family members in thirteen countries.
Summary for Patent: 8,859,610
| Title: | Crystalline glycopyrrolate tosylate | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | Salts of glycopyrrolate, including solid forms thereof are herein disclosed. Methods of making glycopyrrolate salts and methods of treating hyperhidrosis with salts of glycopyrrolate are disclosed. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | John Allan STATLER, Anthony Adrian SHAW, Delphine Caroline Imbert, Jennifer Leigh NELSON, Patricia Andres, Lisa Lynn McQueen, Stephan Xander Mattheus BOERRIGTER | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | Aptuit LLC , Journey Medical Corp | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | US14/024,484 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,859,610 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Patent Claim Types: see list of patent claims | Use; Formulation; Dosage form; | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims: | US Patent 8,859,610: Scope, Claims, Expiration, and Glycopyrronium Tosylate Patent LandscapeUS Patent 8,859,610 protects topical pharmaceutical solutions containing racemic glycopyrronium tosylate, including administration for hyperhidrosis and delivery through an absorbent pad. Its commercial relevance is tied to Qbrexza, the glycopyrronium tosylate topical cloth approved by the FDA for primary axillary hyperhidrosis. The patent does not claim glycopyrronium tosylate as a compound. It claims specified topical compositions, absorbent-pad presentations, and methods of treating hyperhidrosis. The patent was issued October 14, 2014, to Dermira, Inc. Its earliest identified priority date is March 31, 2011. The standard patent-term endpoint is March 31, 2031, before any applicable patent-term adjustment or terminal-disclaimer effects. The patent is within the commercial exclusivity period for Qbrexza’s topical delivery technology. [1,2] What drug and active ingredient does US Patent 8,859,610 cover?The claimed active ingredient is glycopyrronium tosylate, also known as glycopyrrolate tosylate or glycopyrronium p-toluenesulfonate. The claims describe the substance through its two stereochemical components:
The claimed composition must contain a racemic mixture of those two forms, or a solvate.
What are the independent claims in US 8,859,610?Claims 1, 2, and 3 are the principal independent claims. Claim 1: absorbent padClaim 1 covers an absorbent pad containing an absorbed pharmaceutically acceptable solution of racemic glycopyrronium tosylate, or a solvate, together with one or more pharmaceutically acceptable additives. This is a product claim directed to a delivery article rather than merely to a liquid formulation. A wipe, cloth, swab, sponge, or comparable absorbent article may fall within the claim if it contains the required solution and the remaining claim elements are met. The claim does not expressly require:
The required features are the absorbent pad, the solution, the racemic glycopyrronium tosylate or solvate, and at least one pharmaceutically acceptable additive. Claim 2: topical solutionClaim 2 covers a pharmaceutically acceptable solution of the racemic salt mixture or a solvate, with one or more pharmaceutically acceptable additives, for topical administration. This claim is broader than the pad claims because it does not require an absorbent pad. A bottle, pump, dropper, applicator, spray, or other topical solution container could potentially fall within the claim if the formulation and intended topical use satisfy the limitations. The claim does not expressly require treatment of hyperhidrosis. That limitation appears in claim 3. Claim 3: method of treating hyperhidrosisClaim 3 covers topically administering a therapeutically effective amount of the claimed solution to mammalian skin to treat hyperhidrosis. The method requires:
The method is not limited to humans until claim 4. Claim 4 narrows the method to a human patient. How do claims 4 through 14 narrow the patent scope?Claims 4 through 14 create a series of dependent method claims.
Claims 11 through 14 are commercially important because they combine the therapeutic method with both a body site and an absorbent pad. For Qbrexza, the strongest direct overlap is likely with:
What do claims 15 through 28 protect?Claims 15 through 28 add ethanol as an express pharmaceutically acceptable additive. They track claims 1 through 14 and require that ethanol be present in the claimed solution. These claims create narrower fallback positions if a broader composition or method claim is challenged. The ethanol claims are commercially relevant because the Qbrexza product contains ethanol as part of its topical formulation. The claims do not, on their face, require a particular ethanol concentration. They also do not expressly limit the formulation to ethanol as the only solvent or additive. The dependent-claim structure is unusually broad in geographic and delivery coverage:
What formulation characteristics are protected?The patent’s formulation protection is centered on a solution containing racemic glycopyrronium tosylate and at least one pharmaceutically acceptable additive. The claims do not expressly specify:
That creates both breadth and litigation risk. Broad composition claims can reach multiple commercial formulations, but their validity may depend on written-description, enablement, anticipation, and obviousness analysis across the full scope of the claimed solution. How does the patent treat a solvate?The claims expressly include “a solvate thereof.” This language potentially reaches solvated forms of the racemic glycopyrronium tosylate, subject to the ordinary requirements of claim construction and proof of the relevant solid or solution state. A product using a hydrate, alcohol solvate, or other characterized solvate could therefore face claim exposure if the product otherwise satisfies the solution and topical-use limitations. Does US 8,859,610 claim the active ingredient itself?No. The claims supplied do not claim glycopyrronium tosylate as a standalone chemical compound. The patent claims:
A competing product containing the same active ingredient could avoid this patent only if it falls outside the relevant composition, delivery, or method limitations. For example, changing the administration route from topical to oral would generally remove the product from the topical composition and method claims, although other patents could apply. Switching from a solution to a genuinely different dosage form could also matter, but the technical characterization would be fact-specific. What is the FDA status of the related product?Qbrexza is the primary marketed product associated with the patent technology. It is a topical glycopyrronium tosylate cloth approved under FDA NDA 210361 for primary axillary hyperhidrosis in adults and pediatric patients age nine years and older. The FDA approved Qbrexza on June 29, 2018. [3]
Qbrexza’s approved label directs application to each underarm using a single cloth. The label also warns against application to broken skin and contact with the eyes. Those labeling details are relevant to method-of-use and induced-infringement analysis but do not alter the literal scope of the patent claims. [3] What is the Orange Book status of US 8,859,610?US 8,859,610 is associated with the Qbrexza patent estate and has been identified in public drug-patent records as an Orange Book-listed patent for the product. Orange Book listing is important because it can trigger the Hatch-Waxman patent-certification framework for an ANDA applicant. [4] An ANDA applicant seeking approval for a generic equivalent may need to submit:
A Paragraph IV certification can create litigation risk for the applicant and may trigger a 30-month stay of approval if the patent holder files suit within the statutory period. [5] The patent claims are particularly relevant to a generic cloth or wipe that uses:
Are there Paragraph IV challenges or generic litigation?The patent number alone does not establish a Paragraph IV filing, a notice letter, or a filed infringement action. A Paragraph IV challenge is an ANDA applicant’s statutory certification and is not created by the existence of a patent or an Orange Book listing. Publicly available regulatory and court records should be evaluated separately for:
The supplied claim set contains no settlement terms, license terms, litigation judgment, or validity ruling. It therefore provides no basis for concluding that the patent has been invalidated, narrowed, or licensed to a generic competitor. How strong is the patent estate for Qbrexza?US 8,859,610 has meaningful commercial coverage because it combines three claim categories:
That combination creates multiple infringement theories around a Qbrexza-type product. A competing topical cloth could face product claims even before considering the method claims. A topical solution sold in a bottle could avoid the pad claims but remain exposed to the solution claims. A product marketed for hyperhidrosis could face method claims if it is used according to the patented treatment protocol. The principal weaknesses are claim-specific rather than commercial:
The patent is stronger against a close Qbrexza substitute than against a materially different anticholinergic product, a non-solution dosage form, or a different active pharmaceutical ingredient. How does US 8,859,610 compare with competing hyperhidrosis patents?The relevant competitive patent landscape includes four categories.
Competing products such as topical aluminum chloride, botulinum toxin products, oral anticholinergics, and energy-based devices operate under different patent profiles. A product that does not contain glycopyrronium tosylate will generally not fall within the active-ingredient limitation of US 8,859,610, although it may face separate patents. Biosimilar risk is not material to this patent. Qbrexza is a small-molecule drug, not a biologic, and generic entry would proceed through an ANDA rather than a biosimilar application under the Public Health Service Act. What generic launch scenarios exist?Scenario 1: Generic topical clothThis is the highest-overlap scenario. A generic cloth containing racemic glycopyrronium tosylate in solution could implicate claims 1, 3, 4, 5, 9, 10, 11, and the corresponding ethanol claims. Scenario 2: Generic topical liquidA bottle or pump formulation could avoid the absorbent-pad claims but remain exposed to claim 2 and the related topical-treatment claims. Scenario 3: Non-ethanol formulationRemoving ethanol could avoid claims 15 through 28, but it would not necessarily avoid claims 1 through 14. Scenario 4: Different glycopyrronium formA product using a different salt, stereochemical composition, or non-solvated form could present a non-infringement position. The success of that position would depend on whether the product still contains the claimed racemic mixture or a covered solvate. Scenario 5: Different active ingredientA topical formulation using oxybutynin, sofpironium, aluminum chloride, or another active ingredient would generally avoid the active-ingredient limitation of this patent, although it would require a separate freedom-to-operate review. What geographic coverage does the patent provide?US 8,859,610 provides protection only in the United States. Corresponding international or foreign-family applications may protect related subject matter in other jurisdictions, but a US patent cannot be asserted against conduct occurring entirely outside the United States. Foreign analysis requires separate review of:
The US patent’s commercial importance is greatest in the US market because Qbrexza received FDA approval there and the claims map directly to the US-approved cloth presentation. What manufacturing and intellectual-property barriers remain?A generic manufacturer must address more than the active ingredient. The principal barriers include:
Manufacturing-process patents are not apparent from the claims supplied for US 8,859,610. The patent is directed principally to the composition, delivery article, and therapeutic use rather than a detailed synthesis or cloth-manufacturing process. What is the commercial exposure from US 8,859,610?The patent is commercially significant because the claims reach the core Qbrexza product architecture:
Revenue exposure depends on the share of sales represented by the US Qbrexza franchise, the existence of continuation patents, generic filing activity, and the enforceability of the listed claims. Patent expiration alone does not determine the earliest generic launch date if other Orange Book-listed patents remain in force. Key Takeaways
FAQs About US Patent 8,859,610Does US 8,859,610 cover Qbrexza?Yes. The claims materially overlap with Qbrexza’s glycopyrronium tosylate topical cloth, particularly the absorbent-pad, topical-solution, human-treatment, and axillary-use claims. Can a generic avoid US 8,859,610 by removing ethanol?Removing ethanol could avoid the ethanol-dependent claims, but it would not necessarily avoid the broader claims that require only a pharmaceutically acceptable additive. Does the patent cover treatment of palmar or plantar hyperhidrosis?Claims 6 and 7 expressly recite application to the hands and feet. Those claims create additional method coverage beyond axillary treatment. Is a topical spray necessarily outside the patent?No. A spray could avoid the absorbent-pad claims, but a spray containing the claimed racemic glycopyrronium tosylate in a pharmaceutically acceptable topical solution could still implicate the solution and method claims. Does patent expiration guarantee immediate generic Qbrexza entry?No. Generic entry may also depend on other listed patents, regulatory requirements, Paragraph IV litigation, settlements, exclusivity periods, and the generic applicant’s ability to obtain FDA approval. References
More… ↓ |
Drugs Protected by US Patent 8,859,610
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | QBREXZA | glycopyrronium tosylate | CLOTH;TOPICAL | 210361-001 | Jun 28, 2018 | RX | Yes | Yes | 8,859,610 | ⤷ Start Trial | Y | TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,859,610
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014223172 | ⤷ Start Trial | |||
| Australia | 2016269524 | ⤷ Start Trial | |||
| Canada | 2902795 | ⤷ Start Trial | |||
| China | 105026369 | ⤷ Start Trial | |||
| European Patent Office | 2961734 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
